A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 10, 1997, Pages 555-559

  Shiba, Eiichi ^a   Kim, Seung Jin ^a   Taguchi, Tetsuya ^a   Izukura, Masaaki ^a   Kobayashi, Tetsuro ^a   Furukawa, Junkoh ^b   Yayoi, Eiji ^b   Shin, Eisei ^c   Takatsuka, Yuichi ^c   Koyama, Hiroki ^d   Takai, Shin Ichiro ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NTT CORPORATION   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d CENTER FOR ADULT DISEASES   (Japan)

Author keywords

Breast cancer; Prognostic factor; Urokinase type plasminogen activator

Indexed keywords

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INVASION; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

AGE FACTORS; BREAST NEOPLASMS; CYTOSOL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; RISK; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 9844236464     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050104     Document Type: Article

References (14)

1. Abe R, Tsuchiya A, Koie H, Ono K, Abo S, et al (1994) A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan. Am J Clin Oncol 17:103-108
2. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139-266
3. Duffy MJ (1987) Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 23:583-589
4. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829
5. Foekens JA, Schmitt M, Putten WLJV, Peters HA, Bontenbal M, Janicke F, Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105
6. Gray R, Clarke M, Collins R, Peto R (1993) The EBCTCG over-view of adjuvant therapy of breast cancer. What are the implications for future studies? Early Breast Cancer Trialists' Collaborative Group. Ann N Y Acad Sci 698:339-348
7. Grondahl-Hansen J, Christensen U, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521
8. Hermaneck P, Sobin LH (eds) (1992) International Union Against Cancer: TNM classification of malignant tumors, 4th edn. Springer, Berlin Heidelberg New York, pp 43-46
9. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208
10. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, et al (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54:2527-2530
11. Mullins DE, Rohrlich ST (1983) The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695:177-214
12. Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S, O'Connell J, Docherty A (1994) Regulation of matrix metalloproteinases. Ann N Y Acad Sci 732:31-41
13. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H (1992) Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 373:611-622
14. 3H-R5020. Clin Chem 27:687-691